HER—2在骨肉瘤患者中的表达

Expression of HER—2 in Human Osteosarcoma

为观察HER—2在骨肉瘤中的表达,探讨其在骨肉瘤发生、发展中的作用,对38例骨肉瘤患者的临床病理资料进行回顾性研究。应用免疫组化SP法检测骨肉瘤组织38例中HER—2的表达;流式细胞术检测骨肉瘤细胞系中HER—2表达。结果55.3%的骨肉瘤组织HER—2表达阳性,骨肉瘤细胞系中HER—2表达为42.9%,高表达的骨肉瘤患者预后较差。说明在骨肉瘤组织中HER—2表达异常,提示可能对骨肉瘤的发展及预后判断有一定价值,也为骨肉瘤的治疗提供了一种可能的生物靶点。

To detect the expressions of HER—2 in osteosarcoma,and explore their correlation with the occurrence,development of the tumor,the clinicopathologic information of thirty-eight patients with osteosarcoma was studied retro-spectively.The expression of HER—2 in the chosen specimen was assessed by standard immuno-histochemical staining.And the expression of HER—2 in osteosarcoma cell line SOSP—9607 was tested by flow cytometry（FCM）.The results are that 55.3% of the specimen are HER—2 positive.And HER—2 is assessed 42.9 % positive in the SOSP—9607 cell line.It is conclused that HER—2 expression is abnonormal in osteosarcoma specimen.It can be one of the important developmental and prognostic factors in osteosarcoma,and considered as a possible target for the gene therapy of osteosarcoma.